Neurogene’s NGN-401 Gets FDA Breakthrough Therapy Status
Breakthrough Therapy designation granted based on interim NGN-401 Phase 1/2 data demonstrating clinically meaningful, durable and multidomain functional improvements for Neurogene’s lead program On track...